[5] [6] The FLOW trial with semaglutide demonstrated significant reductions in kidney outcomes in patients with type 2 diabetes and chronic kidney disease
The impact of effective weight loss therapies can extend far beyond the monthly invoice
Heimbrger SM, Bergmann NC, Augustin R, Gasbjerg LS, Christensen MB, Knop FK (2020) Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease
Control group participants completed the original AUDIT questionnaire, and the participants on medications (i.e., Semaglutide or Tirzepatide) completed an adapted form asking about each question prior to and while on their medication
Your provider will make any necessary dosage or nutritional adjustments to keep your results consistent and your health optimized
It also makes it simpler to stick to their medication plans